PMID- 36186702
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221004
IS  - 1507-1367 (Print)
IS  - 2083-4640 (Electronic)
IS  - 1507-1367 (Linking)
VI  - 27
IP  - 3
DP  - 2022
TI  - Verification of stereotactic radiosurgery plans for multiple brain metastases 
      using a virtual phantom-based procedure.
PG  - 449-457
LID - 10.5603/RPOR.a2022.0042 [doi]
AB  - BACKGROUND: The purpose of this study was to describe the use of the VIPER 
      software for patient-specific quality assurance (PSQA) of single-isocenter 
      multitarget (SIMT) stereotactic radiosurgery (SRS) plans. MATERIALS AND METHODS: 
      Twenty clinical of intensity-modulated (IMRT) SIMT SRS plans were reviewed. A 
      total of 88 brain metastases were included. Number of lesions per plan and their 
      individual volumes ranged from 2 to 35 and from 0.03 to 32.8 cm(3), respectively. 
      Plans were designed with the Eclipse system, and delivered using a Varian CLINAC 
      linac. SRS technique consisted of non-coplanar static-field sliding-window IMRT. 
      Each plan was mapped onto a virtual cylindrical water phantom (VCP) in the 
      Eclipse to calculate a 3D dose distribution (verification plan). The VIPER 
      software reconstructed the 3D dose distribution inside the VCP from the acquired 
      in-air electronic portal image device (EPID) images of the treatment fields. A 3D 
      gamma analysis was used to compare the reconstructed doses to the Eclipse planned 
      doses on the VCP. Gamma passing rates (GPRs) were calculated using 3% global/2 mm 
      criteria and dose thresholds ranged from 10% to 90% of the maximum dose. RESULTS: 
      The averages (+/- 1 SD) of the 3D GPRs over the 20 SRS plans were: 99.9 +/- 0.2%, 
      99.7 +/- 0.3%, 99.6 +/- 0.5%, 99.3 +/- 0.9%,99.1 +/- 1.6%, 99.0 +/- 1.6%, and 98.5 +/- 3.3%, 
      for dose thresholds of 10%, 20%, 30%, 50%, 70%, 80% and 90% respectively. 
      CONCLUSIONS: This work shows the feasibility of the VIPER software for PSQA of 
      SIMT SRS plans, being a reliable alternative to commercially available 2D 
      detector arrays.
CI  - (c) 2022 Greater Poland Cancer Centre.
FAU - Calvo-Ortega, Juan-Francisco
AU  - Calvo-Ortega JF
AD  - Servicio de Oncologia Radioterapica, Hospital Quironsalud Barcelona, Barcelona, 
      Spain.
FAU - Greer, Peter B
AU  - Greer PB
AD  - Department of Radiation Oncology, Calvary Mater Newcastle Hospital, Newcastle, 
      Australia.
FAU - Moragues-Femenia, Sandra
AU  - Moragues-Femenia S
AD  - Servicio de Oncologia Radioterapica, Hospital Quironsalud Barcelona, Barcelona, 
      Spain.
FAU - Pozo-Masso, Miguel
AU  - Pozo-Masso M
AD  - Servicio de Oncologia Radioterapica, Hospital Quironsalud Barcelona, Barcelona, 
      Spain.
FAU - Casals-Farran, Joan
AU  - Casals-Farran J
AD  - Servicio de Oncologia Radioterapica, Hospital Quironsalud Barcelona, Barcelona, 
      Spain.
LA  - eng
PT  - Journal Article
DEP - 20220729
PL  - Poland
TA  - Rep Pract Oncol Radiother
JT  - Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer 
      Center in Poznan and Polish Society of Radiation Oncology
JID - 100885761
PMC - PMC9518761
OTO - NOTNLM
OT  - EPID
OT  - SRS
OT  - single-isocenter
OT  - virtual phantom
COIS- Conflict of interests None declared.
EDAT- 2022/10/04 06:00
MHDA- 2022/10/04 06:01
PMCR- 2022/07/29
CRDT- 2022/10/03 04:38
PHST- 2022/01/27 00:00 [received]
PHST- 2022/03/24 00:00 [accepted]
PHST- 2022/10/03 04:38 [entrez]
PHST- 2022/10/04 06:00 [pubmed]
PHST- 2022/10/04 06:01 [medline]
PHST- 2022/07/29 00:00 [pmc-release]
AID - rpor-27-3-449 [pii]
AID - 10.5603/RPOR.a2022.0042 [doi]
PST - epublish
SO  - Rep Pract Oncol Radiother. 2022 Jul 29;27(3):449-457. doi: 
      10.5603/RPOR.a2022.0042. eCollection 2022.